Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia [Phase 3]
This is a Phase 3 long-term, once-weekly brexpiprazole trial in schizophrenia that is currently active but not recruiting.
-
FDA approval · 2024-10-29FDA Approved: HALOPERIDOL — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for HALOPERIDOL LACTATE by Sagent Pharmaceuticals under anANDA, indicating an approved supplemental …
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia [Phase 3]
This update describes a completed Phase 3 study evaluating the safety, tolerability, and treatment response of paliperidone palmitate in sch…
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) [Phase 3]
Extension study EMERGENT-4 evaluated long-term safety, tolerability, and efficacy of KarXT in adults with schizophrenia; results from this P…
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia [Phase 4]
Phase 4 clinical trial completed evaluating the effectiveness and safety of paliperidone palmitate in adults with acute schizophrenia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 [Phase 3]
Phase 3 study evaluating pharmacokinetics and safety/tolerability of Long-Acting Oral LYN-005 in schizophrenia and schizoaffective disorder …
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: A Study on the Preference of Risperidone Dosage Forms
Clinical trial sponsored by Shanghai Mental Health Center evaluating preferences for risperidone dosage forms across schizophrenia, bipolar …
-
CLINICAL_TRIALS trial_result · 2024-10-22Clinical Trial Update: NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia [NA]
The NST-SPARK trial reports completion of a preliminary study evaluating an augmented reality app delivering recovery-oriented cognitive the…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia [NA]
This update reports results from a completed clinical trial evaluating the efficacy of an early antipsychotic switch in patients with schizo…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia [Phase 3]
An update on a Phase 3 trial evaluating olanzapine-samidorphan tablets for schizophrenia, with the study currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses [NA]
The clinical trial 'Opening Doors to Recovery' for persons with serious mental illnesses has completed and posted results, sponsored by the …
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Adapted Physical Activity Program for Patients Undergoing Antipsychotic Treatment of a First Episode of Psychosis [NA]
This entry reports an ongoing clinical trial evaluating an adapted physical activity program for patients receiving antipsychotic treatment …
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: HDAC Inhibitor Augmentation to Clozapine [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating HDAC inhibitor augmentation to Clozapine for schizophrenia was withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia [Phase 2, Phase 3]
This update reports results from a Phase 2/3 trial evaluating adjunctive Ashwagandha (Withania somnifera) for persistent symptoms in schizop…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: CVN058 Effect on Mismatch Negativity in Schizophrenics [Phase 1]
Phase 1 trial evaluating CVN058 on mismatch negativity in individuals with schizophrenia; the study has completed and results were posted on…
-
FDA approval · 2024-10-04FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Piramal Critical Care Inc.)
FDA approved a generic chlorpromazine hydrochloride product (Original Application) from Piramal Critical Care Inc.
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011) [Phase 1]
Phase 1 study assessing safety, tolerability, and pharmacokinetics of MK-8189 in participants with schizophrenia and in healthy volunteers; …
-
CLINICAL_TRIALS research · 2024-10-02Clinical Trial Update: Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia
National Taiwan University Hospital is recruiting a study on autonomic nervous system function and meridian energy in patients with schizoph…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Investigating the Cognitive Source of Visual Working Memory Impairment in Schizophrenia [NA]
A completed clinical trial evaluating a neurostimulator approach for visual working memory impairment in schizophrenia; no efficacy results …
-
FDA approval · 2024-09-26FDA Approved: COBENFY — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved COBENFY, a combination of xanomeline and trospium chloride, for the treatment of schizophrenia.
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 [Phase 3]
Phase 3 clinical trial update for ALKS 3831 reporting long-term safety, tolerability, and durability of treatment effect; results have been …
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Cigarette Smoking in Smokers With and Without Schizophrenia [NA]
A completed clinical trial compared cigarette smoking in smokers with schizophrenia to those without schizophrenia; results have been posted…
-
CLINICAL_TRIALS research · 2024-09-26Clinical Trial Update: Semantic and Syntactic Computerized Analysis of Free Speech
A clinical trial is evaluating computerized semantic and syntactic analysis of free speech to study psychotic disorders, including schizophr…
-
FDA approval · 2024-09-26FDA Approved: PALIPERIDONE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of paliperidone through an Original Application (ANDA) for Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? [Phase 4]
A Phase 4 trial is evaluating whether a GLP-1 receptor agonist can prevent deterioration of metabolic state in prediabetic and diabetic pati…